Rocket Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Rocket Pharmaceuticals es Gaurav Shah , nombrado en Jan 2018, tiene una permanencia de 6.83 años. compensación anual total es $8.01M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.22% de las acciones de la empresa, por valor de $15.71M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 6.8 años, respectivamente.
Información clave
Gaurav Shah
Chief Executive Officer (CEO)
US$8.0m
Compensación total
| Porcentaje del salario del CEO | 7.8% |
| Permanencia del CEO | 6.8yrs |
| Participación del CEO | 1.2% |
| Permanencia media de la dirección | 3.2yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$258m |
| Jun 30 2024 | n/a | n/a | -US$253m |
| Mar 31 2024 | n/a | n/a | -US$249m |
| Dec 31 2023 | US$8m | US$625k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$253m |
| Jun 30 2023 | n/a | n/a | -US$249m |
| Mar 31 2023 | n/a | n/a | -US$237m |
| Dec 31 2022 | US$7m | US$598k | -US$222m |
| Sep 30 2022 | n/a | n/a | -US$199m |
| Jun 30 2022 | n/a | n/a | -US$192m |
| Mar 31 2022 | n/a | n/a | -US$172m |
| Dec 31 2021 | US$8m | US$590k | -US$169m |
| Sep 30 2021 | n/a | n/a | -US$186m |
| Jun 30 2021 | n/a | n/a | -US$165m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$540k | -US$140m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$89m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$480k | -US$77m |
| Sep 30 2019 | n/a | n/a | -US$85m |
| Jun 30 2019 | n/a | n/a | -US$82m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$6m | US$414k | -US$75m |
Compensación vs. Mercado: La compensación total de Gaurav($USD8.01M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.42M).
Compensación vs. Ingresos: La compensación de Gaurav ha aumentado mientras la empresa no es rentable.
CEO
Gaurav Shah (49 yo)
6.8yrs
Permanencia
US$8,013,553
Compensación
Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Head of R&D | 6.8yrs | US$4.85m | 0.44% $ 5.7m | |
| Chief Technical Officer | 2.3yrs | US$4.38m | 0.062% $ 799.0k | |
| Chief Medical & Gene Therapy Officer | 6.8yrs | US$3.16m | 0.11% $ 1.4m | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| General Counsel | 3yrs | US$1.56m | 0.070% $ 896.9k | |
| Director of Corporate Communications | no data | sin datos | sin datos | |
| Chief People Officer | 3.2yrs | sin datos | sin datos | |
| Senior VP of Clinical Safety & Chief Regulatory Officer | 4.6yrs | sin datos | sin datos | |
| Chief Business Officer | no data | US$2.82m | 0% $ 0 | |
| Chief Commercial Operations & Revenue Officer | less than a year | sin datos | sin datos |
3.2yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RCKT se considera experimentado (3.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Independent Director | 10.3yrs | US$399.99k | 0.13% $ 1.6m | |
| Independent Director | 6.8yrs | US$429.98k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$427.49k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | sin datos | |
| Chairman of the Board | 6.8yrs | US$409.99k | 0.059% $ 756.6k | |
| Independent Director | 6.8yrs | US$417.49k | 0.13% $ 1.6m | |
| Independent Non-Executive Director | 2.7yrs | US$399.99k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$409.99k | 0% $ 0 | |
| Director | 6.8yrs | US$399.99k | 0.22% $ 2.8m | |
| Independent Non- Executive Director | less than a year | US$568.70k | sin datos |
6.8yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de RCKT se considera experimentada (6.8 años de antigüedad promedio).